These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 20132813

  • 1. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
    Montalban AG, Boman E, Chang CD, Ceide SC, Dahl R, Dalesandro D, Delaet NG, Erb E, Ernst J, Gibbs A, Kahl J, Kessler L, Lundström J, Miller S, Nakanishi H, Roberts E, Saiah E, Sullivan R, Wang Z, Larson CJ.
    Eur J Pharmacol; 2010 Apr 25; 632(1-3):93-102. PubMed ID: 20132813
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR, Anderson GD, Burnette BL, Compton RP, Devraj RV, Hirsch JL, Keith RH, Li X, Mbalaviele G, Messing DM, Saabye MJ, Schindler JF, Selness SR, Stillwell LI, Webb EG, Zhang J, Monahan JB.
    J Pharmacol Exp Ther; 2009 Dec 25; 331(3):882-95. PubMed ID: 19720877
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase.
    Chopra P, Kulkarni O, Gupta S, Bajpai M, Kanoje V, Banerjee M, Bansal V, Visaga S, Chatterjee M, Chaira T, Shirumalla RK, Verma AK, Dastidar SG, Sharma G, Ray A.
    Int Immunopharmacol; 2010 Apr 25; 10(4):467-73. PubMed ID: 20093202
    [Abstract] [Full Text] [Related]

  • 5. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
    Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning AM, Peng SL, Goldstein DM, Wong BR.
    J Pharmacol Exp Ther; 2008 Dec 25; 327(3):610-9. PubMed ID: 18776065
    [Abstract] [Full Text] [Related]

  • 6. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
    Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE.
    J Pharmacol Exp Ther; 2000 Apr 25; 293(1):281-8. PubMed ID: 10734180
    [Abstract] [Full Text] [Related]

  • 7. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
    Liu C, Wrobleski ST, Lin J, Ahmed G, Metzger A, Wityak J, Gillooly KM, Shuster DJ, McIntyre KW, Pitt S, Shen DR, Zhang RF, Zhang H, Doweyko AM, Diller D, Henderson I, Barrish JC, Dodd JH, Schieven GL, Leftheris K.
    J Med Chem; 2005 Oct 06; 48(20):6261-70. PubMed ID: 16190753
    [Abstract] [Full Text] [Related]

  • 8. T cell activation signals up-regulate p38 mitogen-activated protein kinase activity and induce TNF-alpha production in a manner distinct from LPS activation of monocytes.
    Schafer PH, Wang L, Wadsworth SA, Davis JE, Siekierka JJ.
    J Immunol; 1999 Jan 15; 162(2):659-68. PubMed ID: 9916683
    [Abstract] [Full Text] [Related]

  • 9. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.
    Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG.
    J Pharmacol Exp Ther; 2005 Dec 15; 315(3):1188-95. PubMed ID: 16126838
    [Abstract] [Full Text] [Related]

  • 10. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
    Lin TH, Metzger A, Diller DJ, Desai M, Henderson I, Ahmed G, Kimble EF, Quadros E, Webb ML.
    J Pharmacol Exp Ther; 2006 Aug 15; 318(2):495-502. PubMed ID: 16702443
    [Abstract] [Full Text] [Related]

  • 11. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
    Miwatashi S, Arikawa Y, Kotani E, Miyamoto M, Naruo K, Kimura H, Tanaka T, Asahi S, Ohkawa S.
    J Med Chem; 2005 Sep 22; 48(19):5966-79. PubMed ID: 16162000
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis.
    Dai SM, Matsuno H, Nakamura H, Nishioka K, Yudoh K.
    Arthritis Rheum; 2004 Feb 22; 50(2):432-43. PubMed ID: 14872485
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
    Hynes J, Dyckman AJ, Lin S, Wrobleski ST, Wu H, Gillooly KM, Kanner SB, Lonial H, Loo D, McIntyre KW, Pitt S, Shen DR, Shuster DJ, Yang X, Zhang R, Behnia K, Zhang H, Marathe PH, Doweyko AM, Tokarski JS, Sack JS, Pokross M, Kiefer SE, Newitt JA, Barrish JC, Dodd J, Schieven GL, Leftheris K.
    J Med Chem; 2008 Jan 10; 51(1):4-16. PubMed ID: 18072718
    [Abstract] [Full Text] [Related]

  • 14. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases.
    Foey AD, Parry SL, Williams LM, Feldmann M, Foxwell BM, Brennan FM.
    J Immunol; 1998 Jan 15; 160(2):920-8. PubMed ID: 9551930
    [Abstract] [Full Text] [Related]

  • 15. Suppression of lipopolysaccharide-induced cytokine production of gingival fibroblasts by a soybean, Kunitz trypsin inhibitor.
    Kobayashi H, Yoshida R, Kanada Y, Fukuda Y, Yagyu T, Inagaki K, Kondo T, Kurita N, Suzuki M, Kanayama N, Terao T.
    J Periodontal Res; 2005 Dec 15; 40(6):461-8. PubMed ID: 16302924
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
    Mbalaviele G, Anderson G, Jones A, De Ciechi P, Settle S, Mnich S, Thiede M, Abu-Amer Y, Portanova J, Monahan J.
    J Pharmacol Exp Ther; 2006 Jun 15; 317(3):1044-53. PubMed ID: 16501068
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
    Liverton NJ, Butcher JW, Claiborne CF, Claremon DA, Libby BE, Nguyen KT, Pitzenberger SM, Selnick HG, Smith GR, Tebben A, Vacca JP, Varga SL, Agarwal L, Dancheck K, Forsyth AJ, Fletcher DS, Frantz B, Hanlon WA, Harper CF, Hofsess SJ, Kostura M, Lin J, Luell S, O'Neill EA, O'Keefe SJ.
    J Med Chem; 1999 Jun 17; 42(12):2180-90. PubMed ID: 10377223
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vivo and in vitro cytokine modulatory activity of newly synthesised 2-aminotetraline derivatives.
    Ruggiero V, Piovesan P, Fabrizi C, Lauro GM, Campo S, Albertoni C, Nucera E, Carminati P, Ghirardi O.
    Shock; 2004 Jan 17; 21(1):77-85. PubMed ID: 14676688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.